Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):222-233. doi: 10.1002/psp4.13072. Epub 2023 Nov 7.
Appropriate antibiotic dosing to ensure early and sufficient target attainment is crucial for improving clinical outcome in critically ill patients. Parametric survival analysis is a preferred modeling method to quantify time-varying antibiotic exposure - response effects, whereas bias may be introduced in hazard functions and survival functions when competing events occur. This study investigated predictors of in-hospital mortality in critically ill patients treated with meropenem by pharmacometric multistate modeling. A multistate model comprising five states (ongoing meropenem treatment, other antibiotic treatment, antibiotic treatment termination, discharge, and death) was developed to capture the transitions in a cohort of 577 critically ill patients treated with meropenem. Various factors were investigated as potential predictors of the transitions, including patient demographics, creatinine clearance calculated by Cockcroft-Gault equation (CLCR ), time that unbound concentrations exceed the minimum inhibitory concentration (fT ), and microbiology-related measures. The probabilities to transit to other states from ongoing meropenem treatment increased over time. A 10 mL/min decrease in CLCR was found to elevate the hazard of transitioning from states of ongoing meropenem treatment and antibiotic treatment termination to the death state by 18%. The attainment of 100% fT significantly increased the transition rate from ongoing meropenem treatment to antibiotic treatment termination (by 9.7%), and was associated with improved survival outcome. The multistate model prospectively assessed predictors of death and can serve as a useful tool for survival analysis in different infection scenarios, particularly when competing risks are present.
为了改善重症患者的临床结局,确保早期和充分的目标药物浓度达到合适的抗生素剂量至关重要。参数生存分析是量化时间变化的抗生素暴露-反应关系的首选建模方法,但是当竞争事件发生时,危险函数和生存函数可能会出现偏差。本研究通过药代动力学多状态模型研究了重症患者接受美罗培南治疗的院内死亡率的预测因素。建立了一个包含五个状态(美罗培南持续治疗、其他抗生素治疗、抗生素治疗终止、出院和死亡)的多状态模型,以捕捉 577 例接受美罗培南治疗的重症患者队列中的状态转变。研究了各种因素作为潜在的状态转变预测因素,包括患者人口统计学特征、 Cockcroft-Gault 方程(CLCR)计算的肌酐清除率、游离浓度超过最低抑菌浓度(fT)的时间以及与微生物学相关的措施。从美罗培南持续治疗到其他状态的转移概率随着时间的推移而增加。发现 CLCR 每降低 10mL/min,从美罗培南持续治疗和抗生素治疗终止状态向死亡状态转变的危险就会增加 18%。达到 100%fT 可显著增加从美罗培南持续治疗向抗生素治疗终止的转变率(增加 9.7%),并与改善生存结局相关。该多状态模型前瞻性评估了死亡的预测因素,可作为不同感染情况下生存分析的有用工具,特别是当存在竞争风险时。